Send us Feedback

Keryx Biopharmaceuticals (KERX)
Analysis
Data
Financials
 
 
 
 
 
 
Industry    (USD)
Annual
FISCAL YEAR ENDING older 31-DEC
2004		 31-DEC
2005		 31-DEC
2006		 31-DEC
2007		 31-DEC
2008		 newer
Total Revenues 809K 574K 534K 1.05M 1.28M
Gross Margin 0% 0% 0% 0% 97.9%
Number of Drugs in Phase II 0 0 0 0 2.00
R&D/Sales Ratio 0% 0% 0% 0% 2962.4%
Research and Development Expense 0 0 0 0 38.0M
Data Sources:
Market and financial statement data provided by NASDAQ, BATS Exchange, SEC and Xignite Inc. Industry and operating metrics collected from company filings via EDGAR online. For more information on sources and calculations click here.
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki